Olympus Co. (OTCMKTS:OLYMY) Short Interest Down 60.1% in July

Olympus Co. (OTCMKTS:OLYMYGet Free Report) was the recipient of a large decrease in short interest in July. As of July 31st, there was short interest totaling 17,276 shares, a decrease of 60.1% from the July 15th total of 43,336 shares. Based on an average daily volume of 100,297 shares, the days-to-cover ratio is currently 0.2 days.

Analyst Ratings Changes

Separately, The Goldman Sachs Group cut shares of Olympus from a “buy” rating to a “neutral” rating in a research report on Monday, June 15th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Get Our Latest Stock Report on OLYMY

Olympus Trading Up 1.5%

Shares of OTCMKTS:OLYMY traded up $0.20 during trading on Friday, hitting $13.15. The company’s stock had a trading volume of 26,117 shares, compared to its average volume of 99,092. Olympus has a fifty-two week low of $8.08 and a fifty-two week high of $13.73. The stock’s 50-day moving average price is $11.06 and its two-hundred day moving average price is $10.55.

Olympus Company Profile

(Get Free Report)

Olympus Corporation is a Tokyo-based manufacturer specializing in precision technology for the medical, scientific and industrial markets. Established in 1919, the company has built an international reputation for optical and digital imaging solutions that encompass endoscopic systems, microscopes, cameras and related accessories. Olympus leverages its expertise in optics, mechanics and electronics to develop instruments designed to advance diagnostics and scientific discovery.

In the healthcare sector, Olympus is best known for its endoscopy products and therapeutic solutions that support minimally invasive procedures in gastroenterology, pulmonology and urology.

Featured Stories

Receive News & Ratings for Olympus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olympus and related companies with MarketBeat.com's FREE daily email newsletter.